SCHEMBL13635543

SCHEMBL13635543

Cc1cccc(-n2c(=O)ccc3cc(C(=O)O)[nH]c32)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH5 Q6P6C2 2/20 0.53
NOTUM Q6P988 1/20 0.46
KDM4E B2RXH2 5/20 0.44
LMNA P02545 2/20 0.44
PIN1 Q13526 1/20 0.43
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 4/20 0.39
USP2 O75604 3/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 3/20 0.39
HTT P42858 2/20 0.39
APLNR P35414 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
MYC P01106 1/20 0.38
POLB P06746 1/20 0.38
HSPA1A P0DMV8 1/20 0.38
ALOX15 P16050 1/20 0.38
NR4A1 P22736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13575334 0.86 HSD17B10 (0.46) ALKBH5KDM4ELMNAPIN1MEN1
SCHEMBL10059660 0.86 SMAD3 (0.42) ALKBH5KDM4ELMNAMEN1KMT2A
SCHEMBL10059674 0.85 ALKBH5 (0.55) ALKBH5NOTUMKDM4EPIN1MEN1
SCHEMBL13635560 0.83 NPC1 (0.51) LMNAMEN1KMT2AHPGDHTT
SCHEMBL13635556 0.82 LMNA (0.47) KDM4ELMNAMEN1KMT2AHSD17B10
SCHEMBL13635579 0.79 ALDH1A1 (0.48) MEN1KMT2AALDH1A1POLB
SCHEMBL10059623 0.77 ALKBH5 (0.50) ALKBH5NOTUMKDM4ELMNAMEN1
SCHEMBL10059614 0.77 HPGD (0.47) ALKBH5NOTUMKDM4ELMNAMEN1
SCHEMBL16541551 0.74 TBXAS1 (0.36) ALKBH5KDM4ELMNAPIN1MEN1
SCHEMBL10059610 0.74 ALKBH5 (0.41) ALKBH5KDM4ELMNAHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130102597-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2013-04-25 US disclosed
US-8304413-B2 Compounds and methods for treating inflammatory and fibrotic disorders INTERMUNE, INC. (US) 2012-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102597-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS MAP3K8, MAP3K1, MAP3K6 ALKBH5 4048/4885NOTUM 3803/4885KDM4E 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.